Erratum to: J Neurooncol DOI 10.1007/s11060-009-0073-4 {#Sec1}
======================================================

In the Absract of the original publication, the level numbers indicated for the**Recommendations** regarding ***SRS plus WBRT vs. WBRT alone*** were incorrect. The correct level numbers are shown below.

**Recommendations**

***SRS plus WBRT vs. WBRT alone***

*Level 1* Single-dose SRS along with WBRT leads to significantly longer patient survival compared with WBRT alone for patients with single metastatic brain tumors who have a KPS ≥ 70.

*Level 1* Single-dose SRS along with WBRT is superior in terms of local tumor control and maintaining functional status when compared to WBRT alone for patients with 1--4 metastatic brain tumors who have a KPS ≥ 70.

*Level 2* Single-dose SRS along with WBRT may lead to significantly longer patient survival than WBRT alone for patients with 2--3 metastatic brain tumors.

*Level 3* There is class III evidence demonstrating that single-dose SRS along with WBRT is superior to WBRT alone for improving patient survival for patients with single or multiple brain metastases and a KPS \< 70.

The online version of the original article can be found under doi:10.1007/s11060-009-0073-4.
